Open AccessIbrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical
Author(s) -
Rong Dong,
Youyou Yan,
Xiaokang Zeng,
Nengming Lin,
Biqin Tan
Publication year - 2022
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s377697
Subject(s) - ibrutinib , cardiotoxicity , bruton's tyrosine kinase , medicine , adverse effect , pharmacology , tyrosine kinase , leukemia , chronic lymphocytic leukemia , chemotherapy , receptor
Ibrutinib is the first-in-class Bruton tyrosine kinase (BTK) inhibitor that has revolutionized the treatment of B cell malignancies. Unfortunately, increased incidences of cardiotoxicity have limited its use. Despite over a decade of research, the biological mechanisms underlying ibrutinib cardiotoxicity remain unclear. In this review, we discuss the pharmacological properties of ibrutinib, the incidence and mechanisms of ibrutinib-induced cardiotoxicity, and practical management to prevent and treat this condition. We also synopsize and discuss the cardiovascular adverse effects related to other more selective BTK inhibitors, which may guide the selection of appropriate BTK inhibitors.